Hojabr Kakavand

List of Publications by Year
in descending order

23	6,150	394421 19	642732 23
papers	citations	h-index	g-index

23	23	23	11797
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	7.0	192
2	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	27.8	1,068
3	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clinical Cancer Research, 2017, 23, 6054-6061.	7.0	75
4	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 2017, 30, 1666-1676.	5.5	150
5	BRAF^{V600E} and NRAS^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 2016, 69, 680-686.	2.9	28
6	Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 2016, 48, 261-266.	0.6	39
7	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 2016, 48, 194-202.	0.6	19
8	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 2015, 47, 683-693.	0.6	9
9	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
10	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitorâ€“Treated Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	7.0	120
11	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 2015, 28, 884-894.	5.5	37
12	<scp>PD</scp>â€L1 expression in melanoma shows marked heterogeneity within and between patients: implications for antiâ€<scp>PD</scp>â€1/<scp>PD</scp>â€<scp>L</scp>1 clinical trials. Pigment Cell and Melanoma Research, 2015, 28, 245-253.	3.3	356
13	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	5.5	76
14	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature Genetics, 2015, 47, 1194-1199.	21.4	221
15	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10995-11000.	7.1	146
16	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Modern Pathology, 2014, 27, 175-183.	5.5	78
17	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 2014, 46, 193-198.	0.6	19
18	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 2014, 111, 292-299.	6.4	93

#	Article	IF	Citations
19	How anti-PD1 treatments are changing the management of melanoma. Melanoma Management, 2014, 1, 165-172.	0.5	5
20	Melanomas of unknown primary have a mutation profile consistent with cutaneous sunâ€exposed melanoma. Pigment Cell and Melanoma Research, 2013, 26, 852-860.	3.3	48
21	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. OncoImmunology, 2013, 2, e25564.	4.6	6
22	BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage. Clinical Cancer Research, 2013, 19, 4589-4598.	7.0	115
23	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. Cell, 2012, 150, 1135-1146.	28.9	688